Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Miriam Marangon, Carlo Visco, Anna Maria Barbui, Annalisa Chiappella, Alberto Fabbri, Simone Ferrero, Sara Galimberti, Stefano Luminari, Gerardo Musuraca, Alessandro Re, Vittorio Ruggero Zilioli, Marco Ladetto
Summary: Mantle Cell Lymphoma (MCL) is a rare lymphoproliferative disorder that has been regarded as incurable since its identification. For two decades, allogeneic transplantation has been the only option capable of ensuring prolonged remissions and potential cure. However, its application has been limited by feasibility constraints and significant toxicity, particularly in elderly patients.
Review
Hematology
Elisabeth Silkenstedt, Kim Linton, Martin Dreyling
Summary: Mantle cell lymphoma (MCL) exhibits heterogeneous behavior, with treatment options needing to be tailored based on individual risk profiles for optimal outcomes. Recent advances in understanding the molecular background of MCL have led to innovative therapies and improved treatment recommendations for primary and relapsed/refractory MCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Katherine Dittrich, Ummugulsum Yildiz-Altay, Fatima Qutab, Danny A. Kwong, Zechuan Rao, Sebastian A. Nievez-Lozano, Heather L. Gardner, Jillian M. Richmond, Cheryl A. London
Summary: This study explored treatment selection for canine DLBCL using gene expression analysis and identified potential biomarkers that may guide the choice of chemoimmunotherapy treatment in dogs.
Article
Hematology
Vincent Camus, Aurelien Belot, Lucie Oberic, David Sibon, Herve Ghesquieres, Catherine Thieblemont, Christophe Fruchart, Olivier Casasnovas, Jean-Marie Michot, Thierry Jo Molina, Andre Bosly, Clementine Joubert, Corinne Haioun, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Olivier Fitoussi, Richard Delarue, Herve Tilly
Summary: The study evaluated the efficacy and survival of different treatment regimens in DLBCL patients, and found that the results of the RCHOP-14 and R-CHOP21 groups were similar in terms of PFS and OS. However, progression or relapse after second-line chemotherapy led to poor prognosis, highlighting the need for novel approaches in first-line and alternative treatments.
Article
Oncology
Kai Kroeger, Jan Siats, Andrea Kerkhoff, Georg Lenz, Matthias Stelljes, Hans Theodor Eich, Gabriele Reinartz
Summary: This study analyzed the long-term outcome of 22 patients with mantle cell lymphoma who underwent total body irradiation (TBI)-based conditioning prior to stem cell transplantation (SCT). The results support the effectiveness of TBI-based high-dose therapy followed by SCT in this unfavorable disease. The use of recently approved agents and traditional SCT opens up possibilities for personalized treatment for MCL.
Review
Medicine, General & Internal
David A. Bond, Peter Martin, Kami J. Maddocks
Summary: The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients with effective treatment options, but also increases the complexity in prioritization and sequencing of these therapies. Various options including chemo-immunotherapy, BTK inhibitors, Lenalidomide, bortezomib, Venetoclax, and CAR-T therapies are available for relapsed MCL, each with their own toxicity profiles, mechanisms of action and efficacy. Future directions in research include exploring combination treatment strategies and new therapies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cell Biology
Nianping Liu, Chen Jiang, Xinfeng Yao, Minghao Fang, Xiaolong Qiao, Lin Zhu, Zongcheng Yang, Xuyuan Gao, Ying Ji, Chaoshi Niu, Chuandong Cheng, Kun Qu, Jun Lin
Summary: This study reveals the intratumor heterogeneity of malignant cells and immune properties of the tumor-immune microenvironment in primary central nervous system diffuse large B-cell lymphoma (PCNS DLBCL) patients using single-cell transcriptomics and chromatin accessibility sequencing. The findings demonstrate diverse malignant programs and immune response related characteristics in PCNS DLBCL. It also identifies unique survival and plasmablast-like programs, as well as clonally expanded exhausted CD8 T cells in PCNS DLBCL.
Editorial Material
Medicine, General & Internal
Dan L. Longo, James O. Armitage
Summary: Treatment for Hodgkin's lymphoma has been a success in modern medicine. The once fatal disorder is now curable in the majority of patients, even in advanced stages. The focus of treatment is on maintaining high cure rates while reducing toxic effects. The best approach for advanced-stage, high-risk patients is currently debated.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Meri Tarockoff, Teresita Gonzalez, Stanislav Ivanov, Jose Sandoval-Sus
Summary: This review summarizes the current treatment strategies for R/R MCL, discusses evolving agents, and provides guidance in treating this complex disease. Advancements in targeted therapy, cellular therapies, and novel therapeutic agents show promising results for refractory and relapsed mantle cell lymphoma.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Hematology
Masamitsu Yanada, Kazuhito Yamamoto
Summary: Hematopoietic cell transplantation (HCT) is an important therapeutic option for younger patients with mantle cell lymphoma (MCL). Autologous HCT is considered established treatment, while allogeneic HCT is generally reserved for relapsed/refractory patients. Risk-adapted approach based on measurable residual disease and genetic information, as well as incorporation of novel drugs into the treatment scheme, will further improve outcomes.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2022)
Review
Oncology
Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
Summary: The increasing use of high-throughput screening has greatly advanced our knowledge on the molecular basis of natural killer/T-cell lymphoma (NKTCL) and revolutionized its treatment. Asparaginase-containing regimens have significantly improved survival outcomes in NKTCL patients. Novel treatment strategies, including targeted antibodies, immune checkpoint inhibitors, and chimeric antigen receptor T cells, are currently being developed for NKTCL and show promising potential for future use.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Cell Biology
Sabrina Manni, Maria Pesavento, Zaira Spinello, Lara Saggin, Arash Arjomand, Anna Fregnani, Laura Quotti Tubi, Greta Scapinello, Carmela Gurrieri, Gianpietro Semenzato, Livio Trentin, Francesco Piazza
Summary: CK2 is an overexpressed kinase in many solid and blood-derived tumors. This study demonstrates that CK2 sustains MCL cell proliferation, survival, and anti-apoptotic ability, and is involved in BCR and Bcl-2 related signaling. CK2 inactivation enhances the cytotoxicity of Ibrutinib and Venetoclax, offering a potential strategy to overcome drug resistance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Dongfeng Zeng, Yu Fang, Yue Fei, Rong Liang, Haige Ye, Yun Liang, Xiuhua Sun, Michael Wang, Huiqiang Huang, Lugui Qiu, Yuxuan Che, Panpan Liu, Yi Wang, Tao Pan, Yao Lv, Jintai Deng, Shuhua Yi, Yizi He, Ling Xiao, Huijuan Lv, Jiangfang Feng, Huilai Zhang, Hui Zhou, Dehui Zou, Qingqing Cai
Summary: A real-world multicenter study conducted in China evaluated treatment patterns and outcomes in newly diagnosed MCL patients treated with BTK inhibitors. The study found that non-HD-AraC chemotherapy combined with BTK inhibitors may be a viable therapeutic strategy for younger patients, and anti-HBV prophylaxis should be implemented in patients with resolved hepatitis B.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Oncology
Mubarak Al-Mansour
Summary: Mantle cell lymphoma (MCL) accounts for a small percentage of non-Hodgkin lymphoma cases, but its incidence has been increasing steadily. The management of relapsed/refractory MCL remains challenging, with wide variations in recommended treatment approaches. The introduction of new agents, particularly BTK inhibitors, has significantly changed the treatment landscape for R/R MCL patients. However, BTK resistance is common, necessitating further research for more durable responses. Novel agents targeting B-cell receptor signaling have shown clinical activity and tolerable safety profiles. Combination strategies have been investigated to improve the response rates. This report provides an updated literature review on the safety and efficacy of novel therapies for the management of R/R MCL.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Letter
Oncology
Esther Martinez-Font, Oliver Vogler, Regina Alemany, Antonia Obrador-Hevia
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Oncology
Esther Martinez-Font, Irene Felipe-Abrio, Silvia Calabuig-Farinas, Rafael Ramos, Josefa Terrasa, Oliver Vogler, Regina Alemany, Javier Martin-Broto, Antonia Obrador-Hevia
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Oncology
William D. Marrero, Alexis Cruz-Chacon, Christian Castillo, Fernando Cabanillas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2018)
Article
Oncology
Guillem Ramis, Ruth Villalonga-Planells, Margalida Serra-Sitjar, Marta Brell, Silvia Fernandez de Mattos, Priam Villalonga
Article
Chemistry, Medicinal
Cristina Galiana-Rosello, Clara Aceves-Luquero, Jorge Gonzalez, Alvaro Martinez-Camarena, Ruth Villalonga, Silvia Fernandez de Mattos, Concepcion Soriano, Jose Llinares, Enrique Garcia-Espana, Priam Villalonga, Maria Eugenia Gonzalez-Rosende
JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Article
Cell Biology
Patricia Mondelo-Macia, Carmela Rodriguez-Lopez, Laura Valina, Santiago Aguin, Luis Leon-Mateos, Jorge Garcia-Gonzalez, Alicia Abalo, Oscar Rapado-Gonzalez, Mercedes Suarez-Cunqueiro, Angel Diaz-Lagares, Teresa Curiel, Silvia Calabuig-Farinas, Aitor Azkarate, Antonia Obrador-Hevia, Ihab Abdulkader, Laura Muinelo-Romay, Roberto Diaz-Pena, Rafael Lopez-Lopez
Review
Cell Biology
Paula Martinez-Delgado, Serena Lacerenza, Antonia Obrador-Hevia, Maria Lopez-Alvarez, Jose L. Mondaza-Hernandez, Elena Blanco-Alcaina, Paloma Sanchez-Bustos, Nadia Hindi, David S. Moura, Javier Martin-Broto
Article
Pathology
Andrea Moreno-Manuel, Silvia Calabuig-Farinas, Antonia Obrador-Hevia, Ana Blasco, Amaya Fernandez-Diaz, Rafael Sirera, Carlos Camps, Eloisa Jantus-Lewintre
Summary: In oncology, precision medicine has been achieved through biomarker-driven therapies and the use of liquid biopsy technology, particularly through the sensitive and efficient detection method of digital PCR (dPCR). Despite some challenges like multiplexing capacity and protocol standardization, dPCR is considered one of the most sensitive methods for LB analysis and complements next generation sequencing (NGS) in treatment monitoring and minimal residual disease assessment.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2021)
Article
Oncology
Mar Giner-Calabuig, Seila De Leon, Julian Wang, Tara D. Fehlmann, Chinedu Ukaegbu, Joanna Gibson, Miren Alustiza-Fernandez, Maria-Dolores Pico, Cristina Alenda, Maite Herraiz, Marta Carrillo-Palau, Inmaculada Salces, Josep Reyes, Silvia P. Ortega, Antonia Obrador-Hevia, Michael Cecchini, Sapna Syngal, Elena Stoffel, Nathan A. Ellis, Joann Sweasy, Rodrigo Jover, Xavier Llor, Rosa M. Xicola
Summary: This study provides a molecular characterization of MMR-deficient tumors, revealing the variability in their mutational profiles and highlighting the importance of accurate diagnosis and treatment for personalized medicine.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Borja Sese, Sandra Iniguez-Munoz, Miquel Ensenyat-Mendez, Pere Llinas-Arias, Guillem Ramis, Javier I. J. Orozco, Silvia Fernandez de Mattos, Priam Villalonga, Diego M. Marzese
Summary: This study identifies a subpopulation of glioma stem cells (GSCs), known as core-GSCs (c-GSCs), in glioblastoma (GBM) patients that have a similar profile to embryonic stem cells (ESCs) and downregulated immune-associated pathways. The development of an induced c-GSC (ic-GSC) cellular model provides insights into the immune evasion mechanisms in GBM and potential targets for improving immunotherapy treatments.
Review
Biochemistry & Molecular Biology
Aina Martin-Medina, Noemi Ceron-Pisa, Esther Martinez-Font, Hanaa Shafiek, Antonia Obrador-Hevia, Jaume Sauleda, Amanda Iglesias
Summary: The interaction between TLR and WNT signaling pathways in the lung plays a crucial role in the development and metastasis of lung cancer. Understanding this interaction may contribute to the development of new targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Margalida Esteva-Socias, Monica Enver-Sumaya, Cristina Gomez-Bellvert, Monica Guillot, Aitor Azkarate, Raquel Marse, Ursula Sastre, Ana Blasco, Silvia Calabuig-Farinas, Victor Jose Asensio, Josefa Terrasa, Antonia Obrador-Hevia
FRONTIERS IN MEDICINE
(2020)
Article
Oncology
Regina Alemany, David S. Moura, Andres Redondo, Javier Martinez-Trufero, Silvia Calabuig, Carlos Saus, Antonia Obrador-Hevia, Rafael Ramos, Victor H. Villar, Claudia Valverde, Maria Angeles Vaz, Javier Medina, Irene Felipe-Abrio, Nadia Hindi, Miguel Taron, Javier Martin-Broto
CLINICAL CANCER RESEARCH
(2018)
Article
Hematology
Peter Martin, Zhengming Chen, Bruce D. Cheson, Katherine S. Robinson, Michael Williams, Saurabh A. Rajguru, Jonathan W. Friedberg, Richard H. van der Jagt, Ann S. LaCasce, Robin Joyce, Kristen N. Ganjoo, Nancy L. Bartlett, Bernard Lemieux, Ari VanderWalde, Jordan Herst, Jeffrey Szer, Michael H. Bar, Fernando Cabanillas, Anthony J. Dodds, Paul G. Montgomery, Bryn Pressnail, Tricia Ellis, Mitchell R. Smith, John P. Leonard
BRITISH JOURNAL OF HAEMATOLOGY
(2017)
Article
Hematology
Loretta J. Nastoupil, Peter McLaughlin, Lei Feng, Sattva S. Neelapu, Felipe Samaniego, Fredrick B. Hagemeister, Ana Ayala, Jorge E. Romaguera, Andre H. Goy, Eleanor Neal, Michael Wang, Luis Fayad, Michelle A. Fanale, Yasuhiro Oki, Jason R. Westin, Maria A. Rodriguez, Fernando Cabanillas, Nathan H. Fowler
BRITISH JOURNAL OF HAEMATOLOGY
(2017)